Business
Treace Announces New ALIGN3D™ Data at the 2021 AOFAS Annual Meeting
PONTE VEDRA, Fla., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace”) (Nasdaq: TMCI), a commercial-stage orthopaedic medical device
About this update from Treace Medical Concepts, Inc.
[{"type":"text","content":"PONTE VEDRA, Fla., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace”) (Nasdaq: TMCI), a commercial-stage orthopaedic medical device company driving a paradigm shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction™ procedure, today announced the presentation of new data at the ongoing 2021 American Orthopaedic Foot & Ankle Society (AOFAS) Annual Meeting in Charlotte, North Carolina. Updated interim analysis from the ALIGN3D™ clinical study demonstrated positive radiographic and patient-reported outcomes starting at 6 weeks and maintained at 24 months following the Lapiplasty® procedure. “Results of an Interim Analysis of a Prospective Multicenter Study Assessing Radiographic and Patient Outcomes Following Triplanar Tarsometatarsal Arthrodesis with Early Weightbearing” was highlighted during the poster presentations. Data on 151 study participants showed: Early return to weight bearing in a walking boot at an average 8.3 days;Significant improvement in radiographic measures of 3-dimensional bunion correction and patient reported pain reduction and quality of life measurements at 12 months (n=104) and through 24 months (n=28) following the Lapiplasty® procedure;Return to work within 4 weeks and to full, unrestricted activity within 4.1 months of procedure; andLow recurrence rate maintained; 0.9% recurrence rate observed (1 out of 104 patients) at 12 months post-surgery. John T. Treace, CEO of Treace commented, “New data continues to demonstrate sustained successful procedural and patient outcomes from our proprietary Lapiplasty® System, specifically designed to address the unmet needs of bunion patients. We are pleased with our growing body of clinical evidence that support our differentiated solution, as we advance the standard of care for bunion surgery with our proprietary Lapiplasty® procedure.” A poster summarizing the data and conclusions can be accessed by meeting attendees through the AOFAS mobile app. About the ALIGN3D™ Clinical StudyThe ALIGN3D™ clinical study is a prospective, multicenter, post-market study designed to evaluate outcomes of Lapiplasty® 3D Bunion Correction™ in the surgical management of symptomatic hallux valgus. The study will evaluate for consistent and reliable correction of all three dimensions of the bunion d...